



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Replication of associations between GWAS SNPs and melanoma risk in the Population Architecture using Genomics and Epidemiology (PAGE) study

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Kocarnik, J. M., S. L. Park, J. Han, L. Dumitrescu, I. Cheng, L. R. Wilkens, F. R. Schumacher, et al. 2014. "Replication of associations between GWAS SNPs and melanoma risk in the Population Architecture using Genomics and Epidemiology (PAGE) study." <i>The Journal of investigative dermatology</i> 134 (7): 2049-2052. doi:10.1038/jid.2014.53. http://dx.doi.org/10.1038/jid.2014.53 .
Published Version	doi:10.1038/jid.2014.53
Accessed	February 17, 2015 12:39:19 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890797
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)



Published in final edited form as:

J Invest Dermatol. 2014 July ; 134(7): 2049–2052. doi:10.1038/jid.2014.53.

Replication of associations between GWAS SNPs and melanoma risk in the Population Architecture using Genomics and Epidemiology (PAGE) study

Jonathan M Kocarnik¹, S Lani Park², Jiali Han^{3,4}, Logan Dumitrescu^{5,6}, Iona Cheng⁷, Lynne R Wilkens², Fredrick R Schumacher⁸, Laurence Kolonel², Chris S Carlson¹, Dana C Crawford^{5,6}, Robert J Goodloe⁵, Holli Dilks⁵, Paxton Baker⁵, Danielle Richardson⁵, José Luis Ambite⁹, Fengju Song^{3,10}, Abrar A Quresh¹¹, Mingfeng Zhang¹¹, David Duggan¹², Carolyn Hutter¹³, Lucia A Hindorff¹⁴, William S Bush^{5,15}, Charles Kooperberg¹, Loic Le Marchand², and Ulrike Peters¹

¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA

²Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI

³Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

⁴Department of Epidemiology, Fairbanks School of Public Health, Simon Cancer Center, Indiana University, Indianapolis, IN

⁵Center for Human Genetics Research, Vanderbilt University, Nashville, TN

⁶Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN

⁷Cancer Prevention Institute of California, Fremont, CA

⁸Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA

⁹Information Sciences Institute, University of Southern California, Marina del Rey, CA

¹⁰Department of Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

¹¹Department of Dermatology, Brigham and Women's Hospital, Boston, MA

¹²Translational Genomics Research Institute, Phoenix, AZ

¹³Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, NCI, NIH, Bethesda, MD

¹⁴Division of Genomic Medicine, NHGRI, NIH, Bethesda, MD

Corresponding authors: Ulrike Peters, 1100 Fairview Ave N, M4-B402 / PO Box 19024, Seattle, WA 98109, upeters@fhcrc.org, Phone: (206) 667-2879, Fax: (206) 667-7850, Jonathan M. Kocarnik, 1100 Fairview Ave N, M4-B402 / PO Box 19024, Seattle, WA 98109, jkocarni@fhcrc.org, Phone: (206) 667-5257, Fax: (206) 667-7850.

Work primarily performed in Seattle, WA, USA. Additional work performed in: Boston, MA, USA; Honolulu, HI, USA; Nashville, TN, USA

Conflict of Interest: The authors state no conflict of interest.

¹⁵Department of Biomedical Informatics, Vanderbilt University, Nashville, TN

To the Editor

Melanoma is a considerable public health burden, with an estimated 76,690 new diagnoses and 9,480 deaths from melanoma in the United States in 2013 alone (Howlander *et al.*, 2013). Multiplex families have pointed to important genetic factors for melanoma, including high-penetrance risk loci such as *CDKN2A* or *CDK4* (Gruber and Armstrong, 2006). In sporadic disease, genome-wide association studies (GWAS) have also successfully identified at least 8 single nucleotide polymorphisms (SNPs) associated with melanoma (Gerstenblith *et al.*, 2010). Our study aimed to replicate these existing GWAS findings within the large Population Architecture using Genomics and Epidemiology (PAGE) study in order to further evaluate their association with melanoma.

In addition to genetic factors, other risk factors for melanoma include exposure to natural and artificial ultraviolet radiation, larger numbers of nevi, pigmentation traits (light versus dark hair, eye, and skin color), race/ethnicity (European versus non-European ancestry), skin response to UV exposure (burn versus tan), older age, and male sex (Gruber and Armstrong, 2006). Anatomic location of melanoma also tends to vary by sex, arising most commonly on the back, abdomen, and chest in males, and on the lower leg, hip, and thigh in females (Gruber and Armstrong, 2006). Females also appear to have lower risk of metastases and longer melanoma-specific survival than males (Joosse *et al.*, 2011). As melanoma risk, anatomic location, and survival have been shown to vary by sex, this study also aimed to evaluate whether genetic associations with melanoma differed by sex as well.

To answer these questions, we evaluated 2,131 invasive melanoma cases and 20,353 melanoma-free controls from five study populations (Table S1). Three studies collaborated through their participation in the PAGE study (Matise *et al.*, 2011): the Multiethnic Cohort (MEC); the Women's Health Initiative (WHI); and Epidemiological Architecture for Genes Linked to Environment (EAGLE), accessing BioVU, the Vanderbilt biorepository linked to de-identified electronic medical records. Two non-PAGE studies also contributed: the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). Additional details for these studies are provided in the Supplementary Materials. All analyses were performed using Stata version 13 (StataCorp LP, College Station, TX).

Study-specific logistic regression estimates evaluated the association between each SNP and melanoma, coded additively for each copy of the purported risk allele. These results were combined using fixed effect inverse-weighted meta-analysis to obtain overall effect estimates. The association between a SNP and melanoma was considered statistically significant if the Bonferroni-corrected p-value was below 0.006 ($=0.05/8$). In order to evaluate for potential sex-specific genetic effects, we also evaluated the association between each SNP and melanoma risk stratified by sex. We performed meta-regression to obtain p-heterogeneity values for the difference between sex-specific regression estimates, using a statistical significance threshold of p-heterogeneity < 0.05. All participants were of European ancestry. HPFS is a male-only study. Since NHS and WHI are female-only studies, the overall analysis included roughly twice as many females as males (Table S1). Melanoma

cases tended to be of similar or older age than controls (overall mean age of 65 in cases vs. 63 in controls), except for in EAGLE-BioVU where controls were younger (mean age 64 in cases vs. 56 in controls).

We evaluated 8 SNPs previously identified by GWAS for an association with melanoma risk (Bishop *et al.*, 2009; Brown *et al.*, 2008; Falchi *et al.*, 2009; Fernandez *et al.*, 2008; Gerstenblith *et al.*, 2010). These SNPs are in or near genes which are likely to be important to melanoma pathways through their potential impact on melanogenesis (*TYR*, *SLC45A2/MATP*, *AFG3LIP/MC1R*, *PIGU/ASIP*), cell cycle regulation (*CDK10*), cell growth and apoptosis (*PLA2G6*), or tumor suppression (*MTAP/CDKN2A*). Results from the meta-analyses across 3-5 studies showed 7 SNPs statistically significantly associated with melanoma at Bonferroni-corrected levels (meta-analysis $p < 0.006$), while the eighth SNP was nominally significant ($p = 0.02$; Table 1). All 8 SNPs showed an association in the same direction and of similar magnitude as previously reported. Six of the 7 significant SNPs showed a modest increase in melanoma risk (OR=1.17–1.55), while rs16891982 showed a much larger effect (OR=3.11).

Sex-stratified analyses showed similar results, with 4 SNPs significantly associated with melanoma in both male-only and female-only meta-analyses at Bonferroni-corrected levels, and 3 SNPs nominally associated in each (meta-analysis $p < 0.05$; Table S2). Only one of these SNPs, rs16891982, showed a potential difference in effect by sex (p -heterogeneity=0.02), with a stronger association in males (OR=5.50, 95% CI: 2.94–10.28) than females (OR=2.37, 95% CI: 1.69–3.31; Table 2, Figure S1). This non-synonymous SNP in the *SLC45A2* gene has previously been associated with melanoma (Duffy *et al.*, 2010; Fernandez *et al.*, 2008; Guedj *et al.*, 2008) and pigmentation traits such as skin and hair color (Stokowski *et al.*, 2007). Also known as *MATP*, this gene encodes an ion transporter protein in the melanosome. Ion and small molecule transport is functionally important to melanogenesis and the pigmentation pathway (Scherer and Kumar, 2010), with ion exchange predicted to impact melanogenesis by playing an important role in regulating melanosome pH levels (Kondo and Hearing, 2011).

Providing biological plausibility for a potential sex difference in effect at this SNP is evidence that skin pigmentation processes can be up- or down-regulated by sex hormones. In a recent study of the hyperpigmentation condition melasma, findings supported the role of several ion transporters, including *SLC26A3*, in the estrogen-induced expression of tyrosinase (Kim *et al.*, 2012). In another study, androgens were shown to have an inhibitory effect on tyrosinase activity (Tadokoro *et al.*, 2003). Tyrosinase is considered the rate-limiting enzyme in melanin synthesis, and regulation of its activity can influence skin pigmentation through the levels of eumelanin and pheomelanin produced (Kondo and Hearing, 2011). Importantly, both tyrosinase levels and tyrosinase activity have also been associated with rs16891982 genotype (Cook *et al.*, 2009). As males and females differ in their circulating levels of sex hormones, it is possible that these hormones impact ion exchange or tyrosinase activity in a way that modifies the effect of this *SLC45A2* variant on melanoma risk, perhaps through alterations to melanogenesis or skin pigmentation. Interestingly, sex differences in the genetic effect of solute carrier genes have also been seen for other phenotypes, such as *LYPLALI/SLC30A10* with waist-hip ratio (Randall *et al.*,

2013). Further research is needed to evaluate these potential sex differences in genetic contributions to melanoma risk.

This study was strengthened by the collaboration of five large studies, which provide sizable samples to evaluate the melanoma GWAS SNP association with melanoma. Limitations included two SNPs that were not available in HPFS and NHS (rs16891982 and rs910873), though both still replicated. An additional limitation is that we were unable to test whether some of our findings are independently associated with melanoma, or are due to an association with pigmentation characteristics. Additional work will be needed to explore the relationships between these genetic variants, pigmentation characteristics, and melanoma.

In summary, this large meta-analysis of five studies successfully replicated seven of eight previous melanoma findings, with the eighth SNP still showing a suggestive effect in the expected direction. Additionally, we observed potential differences in effect by sex for SNP rs16891982 in *SLC45A2*, with a larger effect in males than females. This study reinforces previous evidence that these genetic variants are important for melanoma risk, and for one SNP provides suggestive evidence for a potential sex difference in effect. These results implicate a complex interaction between genetic variants, ion transport, hormones, and pigmentation on melanoma etiology, and demonstrate the potential utility of evaluating sex-specific associations to further elucidate these relationships.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

(a) The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo), U01HG004798 (EAGLE), U01HG004802 (MEC), U01HG004790 (WHI), and U01HG004801 (Coordinating Center), and their respective NHGRI ARRA supplements. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The complete list of PAGE members can be found at <http://www.pagestudy.org>.

(b) The data and materials included in this report results from collaboration between the following studies:

The “Epidemiologic Architecture for Genes Linked to Environment (EAGLE)” is funded through the NHGRI PAGE program (U01HG004798-01 and its NHGRI ARRA supplement). The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by institutional funding and by the Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH. The Vanderbilt University Center for Human Genetics Research, Computational Genomics Core provided computational and/or analytical support for this work.

The Multiethnic Cohort study (MEC) characterization of epidemiological architecture is funded through the NHGRI PAGE program (U01HG004802 and its NHGRI ARRA supplement). The MEC study is funded through the National Cancer Institute (R37CA54281, R01 CA63, P01CA33619, U01CA136792, and U01CA98758).

Funding support for the “Epidemiology of putative genetic variants: The Women's Health Initiative” study is provided through the NHGRI PAGE program (U01HG004790 and its NHGRI ARRA supplement). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: <https://cleo.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf>

Assistance with phenotype harmonization, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by the PAGE Coordinating Center (U01HG004801-01 and its NHGRI ARRA supplement). The National Institutes of Mental Health also contributes to the support for the Coordinating Center.

The Nurses' Health Study and the Health Professionals Followup Study were funded by NIH grants CA122838, CA87969, CA055075, CA49449, CA100264, and CA093459.

Funding for work by author JMK was supported by grants R25CA94880 and T32CA09168 from the National Cancer Institute (NCI), NIH.

The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions.

References

- Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. *Nat Genet.* 2009; 41:920–5. [PubMed: 19578364]
- Brown KM, Macgregor S, Montgomery GW, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. *Nat Genet.* 2008; 40:838–40. [PubMed: 18488026]
- Cook AL, Chen W, Thurber AE, et al. Analysis of cultured human melanocytes based on polymorphisms within the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P loci. *J Invest Dermatol.* 2009; 129:392–405. [PubMed: 18650849]
- Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. *J Invest Dermatol.* 2010; 130:520–8. [PubMed: 19710684]
- Falchi M, Bataille V, Hayward NK, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. *Nat Genet.* 2009; 41:915–9. [PubMed: 19578365]
- Fernandez LP, Milne RL, Pita G, et al. SLC45A2: a novel malignant melanoma-associated gene. *Hum Mutat.* 2008; 29:1161–7. [PubMed: 18563784]
- Gerstenblith MR, Shi J, Landi MT. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. *Pigment Cell Melanoma Res.* 2010; 23:587–606. [PubMed: 20546537]
- Gruber, SB.; Armstrong, BK. Cutaneous and ocular melanoma. In: Schottenfeld, D.; Fraumeni, JF., editors. *Cancer Epidemiology and Prevention*. 3. Oxford University Press; USA: New York, NY: 2006. p. 1126-229.
- Guedj M, Bourillon A, Combadières C, et al. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. *Hum Mutat.* 2008; 29:1154–60. [PubMed: 18683857]
- Howlander, N.; N, A.; Krapcho, M.; Garshell, J., et al., editors. SEER Cancer Statistics Review, 1975-2010. 2013. http://seer.cancer.gov/csr/1975_2010/ Accessed based on November 2012 SEER data submission, posted to the SEER website
- Joesse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. *Journal Invest Dermatol.* 2011; 131:719–26.
- Kim NH, Cheong KA, Lee TR, et al. PDZK1 upregulation in estrogen-related hyperpigmentation in melasma. *J Invest Dermatol.* 2012; 132:2622–31. [PubMed: 22696060]
- Kondo T, Hearing VJ. Update on the regulation of mammalian melanocyte function and skin pigmentation. *Expert Rev Dermatol.* 2011; 6:97–108. [PubMed: 21572549]
- Matisse TC, Ambite JL, Buyske S, et al. The Next PAGE in understanding complex traits: design for the analysis of Population Architecture Using Genetics and Epidemiology (PAGE) Study. *Am J Epidemiol.* 2011; 174:849–59. [PubMed: 21836165]
- Randall JC, Winkler TW, Kutalik Z, et al. Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. *PLoS Genet.* 2013; 9(6):e1003500. [PubMed: 23754948]
- Scherer D, Kumar R. Genetics of pigmentation in skin cancer--a review. *Mutat Res.* 2010; 705:141–53. [PubMed: 20601102]
- Stokowski RP, Pant PV, Dadd T, et al. A genomewide association study of skin pigmentation in a South Asian population. *Am J Hum Genet.* 2007; 81:1119–32. [PubMed: 17999355]

Tadokoro T, Rouzaud F, Itami S, et al. The inhibitory effect of androgen and sex-hormone-binding globulin on the intracellular cAMP level and tyrosinase activity of normal human melanocytes. *Pigment Cell Res.* 2003; 16:190–7. [PubMed: 12753385]

Abbreviations

EAGLE-BioVU	Epidemiologic Architecture of Genes Linked to Environment, accessing BioVU, the Biorepository of Vanderbilt University
GWAS	genome-wide association study
HPFS	Health Professionals Follow-up Study
MEC	Multiethnic Cohort Study
NHS	Nurses' Health Study
PAGE	Population Architecture using Genomics and Epidemiology
SNP	single nucleotide polymorphism
WHI	Women's Health Initiative

Table 1

Meta-analysis results for the association between eight melanoma GWAS SNPs and melanoma.

SNP	Gene	Chromosome / Risk allele	n	# Studies	OR	95% CI	P-value	Study P-heterogeneity
rs258322	<i>CDK10</i>	16 / A	22,082	5	1.55	(1.41 - 1.70)	8.54E-19	0.62
rs4785763	<i>AFG3L1P</i> (near <i>MC1R</i>)	16 / A	21,993	5	1.31	(1.22 - 1.40)	1.01E-14	0.73
rs16891982	<i>SLC45A2</i> (<i>MATP</i>)	5 / G	15,949	3	3.11	(2.31 - 4.18)	7.39E-14	0.43
rs1393350	<i>TYR</i>	11 / A	22,009	5	1.25	(1.17 - 1.35)	6.21E-10	0.80
rs4636294	<i>MTAP</i> (near <i>CDKN2A</i>)	9 / A	22,053	5	1.18	(1.11 - 1.27)	5.51E-07	0.18
rs7023329	<i>MTAP</i> (near <i>CDKN2A</i>)	9 / A	22,114	5	1.17	(1.10 - 1.25)	1.93E-06	0.36
rs910873	<i>P1GU</i> (near <i>ASIP</i>)	20 / A	15,937	3	1.31	(1.15 - 1.48)	2.46E-05	1.00
rs2284063	<i>PLA2G6</i>	22 / G	22,087	5	1.09	(1.01 - 1.16)	0.019	0.27

Bold p-values are statistically significant for replication at a Bonferroni-corrected threshold of 0.05/8=0.006. SNPs rs16891982 and rs910873 were not available in HPFS or NHS. SNPs are ordered by p-value.

Table 2

Sex-stratified meta-analysis of the association between rs16891982 and melanoma.

SNP	Gene	Chromosome / Risk allele	Group	n	# Studies	OR	95% CI	P-value	Study P-heterogeneity	Sex P-heterogeneity
rs16891982	SLC45A2	5 / G	Female	10,160	3	2.37	(1.69 - 3.31)	4.67E-07	0.45	0.02
			Male	5,789	2	5.50	(2.94 - 10.28)	9.53E-08	0.34	

Bold p-values are statistically significant for replication at a Bonferroni-corrected threshold of 0.05/8=0.006. SNP rs16891982 was not available in HPFS (male only) or NHS (female only).